Pancreatic carcinoma is one of the most enigmatic and aggressive malignant diseases. Neoplasms of the pancreas encompass a wide spectrum of benign and malignant tumors. Pancreatic adenocarcinoma, the malignant neoplasm of the exocrine duct cells, accounts for more than ninety percent of all pancreatic tumors (Ref.1). Pancreatic ductal adenocarcinoma evolves from a progressive cascade of cellular, morphological and architectural changes from normal ductal epithelium through pre-neoplastic lesions termed PanIN (Pancreatic Intraepithelial Neoplasia). These PanIN lesions are in turn associated with somatic alterations in canonical oncogenes and tumor suppressor genes. Pancreatic cancer like many other tumors over-expresses the RTKs (Receptor Tyrosine Kinases), EGFR (Epidermal Growth Factor Receptor) and/or its family members (like Her2) and TGF-BetaRs (Transforming Growth Factor-Beta Receptors). The expression of RTKs [...]